Aquestive Therapeutics Inc (NASDAQ:AQST) – Equities research analysts at Wedbush boosted their Q3 2019 earnings per share (EPS) estimates for Aquestive Therapeutics in a research note issued to investors on Wednesday, October 16th. Wedbush analyst L. Moussatos now anticipates that the company will earn ($0.82) per share for the quarter, up from their previous forecast of ($0.84). Wedbush currently has a “Buy” rating and a $34.00 target price on the stock. Wedbush also issued estimates for Aquestive Therapeutics’ Q4 2019 earnings at ($0.83) EPS and FY2019 earnings at ($3.06) EPS.
Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Tuesday, August 6th. The company reported ($0.82) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.15). The business had revenue of $11.13 million for the quarter, compared to the consensus estimate of $10.46 million. Aquestive Therapeutics had a negative return on equity of 8,682.29% and a negative net margin of 119.15%.
A number of other equities research analysts have also recently commented on AQST. Zacks Investment Research upgraded Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday. ValuEngine upgraded Aquestive Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $18.46.
NASDAQ AQST opened at $3.21 on Monday. The stock has a market capitalization of $79.92 million, a price-to-earnings ratio of -1.15 and a beta of 1.84. Aquestive Therapeutics has a one year low of $2.95 and a one year high of $18.49. The business’s fifty day moving average is $3.30 and its 200-day moving average is $4.25.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Wedbush Securities Inc. increased its holdings in Aquestive Therapeutics by 39.2% in the 3rd quarter. Wedbush Securities Inc. now owns 98,489 shares of the company’s stock worth $313,000 after acquiring an additional 27,756 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Aquestive Therapeutics in the 2nd quarter worth about $361,000. Royal Bank of Canada purchased a new stake in Aquestive Therapeutics in the 2nd quarter worth about $249,000. Paloma Partners Management Co purchased a new stake in Aquestive Therapeutics in the 2nd quarter worth about $213,000. Finally, Jane Street Group LLC purchased a new position in Aquestive Therapeutics during the 2nd quarter valued at about $133,000. 66.41% of the stock is owned by institutional investors.
In other news, Director James S. Scibetta acquired 22,971 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The stock was bought at an average price of $3.79 per share, with a total value of $87,060.09. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last three months, insiders purchased 27,871 shares of company stock valued at $121,453. 55.60% of the stock is currently owned by insiders.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.
Recommended Story: Stock Split
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.